search
Back to results

Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation

Primary Purpose

COPD, Chronic Bronchitis, Emphysema

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
pneumatic vest
placebo pneumatic vest
Sponsored by
Johns Hopkins University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for COPD focused on measuring COPD

Eligibility Criteria

45 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Physician Diagnosis of COPD,chronic bronchitis and/or emphysema Forced Expiratory Volume in 1 second (FEV1)/ Forced Vital Capacity (FVC) < or = 70% FEV1 < or = 65% Current or former smoker > or = 20 pack years History of 1 or more COPD exacerbations in past 6 months necessitation hospitalization, Emergency Department (ED) visit, antibiotic or steroid prescription Exclusion Criteria: Other lung diseases Co-morbid illnesses such as cancer, liver disease, cardiomyopathy Recent chest wall or abdominal trauma or surgery that would preclude using the vest

Sites / Locations

  • Johns Hopkins Asthma and Allergy Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Active

Sham

Arm Description

Pneumatic Compression Device used twice daily for 20 minutes each time for 12 weeks

Device looked and sounded like a pneumatic compression device, but was not inflating nor deflating.

Outcomes

Primary Outcome Measures

The Primary Outcome Measure is the Rate of Exacerbations as Defined Using the Winnipeg Criteria.
count of exacerbations per group per 12 weeks. An exacerbation was defined based on three major symptoms: increasing dyspnea, increasing sputum purulence and increasing sputum volume. Exacerbations were counted if there were at least 2 of these 3 symptoms.

Secondary Outcome Measures

Quality of Life
The SF-36 is used to measure health related quality of life. It assesses eight health concepts and provides physical and mental health summary scores. The summary scores range from 0 to 100, with 0 representing the worst and 100 the best quality of life.

Full Information

First Posted
September 13, 2005
Last Updated
February 8, 2018
Sponsor
Johns Hopkins University
Collaborators
Centers for Medicare and Medicaid Services, Hill-Rom
search

1. Study Identification

Unique Protocol Identification Number
NCT00181207
Brief Title
Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
Official Title
A Randomized, Sham-controlled, Double-blinded Pilot Study to Assess the Effects of High Frequency Chest Wall Oscillation (HFCWO) Therapy in Patients With Chronic Bronchitis
Study Type
Interventional

2. Study Status

Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
May 2004 (undefined)
Primary Completion Date
November 2007 (Actual)
Study Completion Date
December 2007 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Johns Hopkins University
Collaborators
Centers for Medicare and Medicaid Services, Hill-Rom

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to show that one form of mechanical airway clearance techniques, High Frequency Chest Wall Oscillation (HFCWO)using a pneumatic vest, will diminish exacerbations of COPD which will improve respiratory health status.
Detailed Description
Approximately 60 to 70% of people with COPD have chronic cough and phlegm, the cardinal symptoms of chronic bronchitis or chronic mucus hypersecretion (CMH). Once thought to be a relatively benign condition, recent evidence shows that CMH in patients with established COPD is associated with greater decline in lung function, more frequent respiratory infections, more frequent exacerbations and increased mortality.Using mechanical airway clearance techniques (The Vest) will diminish exacerbations of COPD which will improve respiratory health status. Comparison: Patients randomly assigned to the vest will have fewer exacerbations of COPD,better quality of life and less health care use compared to patients assigned to a sham vest.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COPD, Chronic Bronchitis, Emphysema
Keywords
COPD

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Active
Arm Type
Experimental
Arm Description
Pneumatic Compression Device used twice daily for 20 minutes each time for 12 weeks
Arm Title
Sham
Arm Type
Placebo Comparator
Arm Description
Device looked and sounded like a pneumatic compression device, but was not inflating nor deflating.
Intervention Type
Device
Intervention Name(s)
pneumatic vest
Intervention Type
Other
Intervention Name(s)
placebo pneumatic vest
Primary Outcome Measure Information:
Title
The Primary Outcome Measure is the Rate of Exacerbations as Defined Using the Winnipeg Criteria.
Description
count of exacerbations per group per 12 weeks. An exacerbation was defined based on three major symptoms: increasing dyspnea, increasing sputum purulence and increasing sputum volume. Exacerbations were counted if there were at least 2 of these 3 symptoms.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Quality of Life
Description
The SF-36 is used to measure health related quality of life. It assesses eight health concepts and provides physical and mental health summary scores. The summary scores range from 0 to 100, with 0 representing the worst and 100 the best quality of life.
Time Frame
Change from baseline to 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Physician Diagnosis of COPD,chronic bronchitis and/or emphysema Forced Expiratory Volume in 1 second (FEV1)/ Forced Vital Capacity (FVC) < or = 70% FEV1 < or = 65% Current or former smoker > or = 20 pack years History of 1 or more COPD exacerbations in past 6 months necessitation hospitalization, Emergency Department (ED) visit, antibiotic or steroid prescription Exclusion Criteria: Other lung diseases Co-morbid illnesses such as cancer, liver disease, cardiomyopathy Recent chest wall or abdominal trauma or surgery that would preclude using the vest
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gregory B Diette, M.D.,M.H.S
Organizational Affiliation
Johns Hopkins University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Johns Hopkins Asthma and Allergy Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21224
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation

We'll reach out to this number within 24 hrs